540 A novel antibody that induces PD-L1 degradation results in enhanced tumor responses in a humanized PD-L1 breast carcinoma mouse model compared to Atezolizumab

• Xin Liu,
• Haidong Dong,
• Fabrice Lucien-Matteoni,
• Michelle Hsu,
• Whitney Barham,
• Sue Harrington

Affiliations

Xin Liu

Keck School of Medicine, University of Southern California, Los Angeles, California, USA

Haidong Dong

Mayo Clinic, Rochester, MN, USA

Fabrice Lucien-Matteoni

1Mayo Clinic, Rochester, MN, USA

Michelle Hsu

Mayo Clinic, Rochester, MN, USA

Whitney Barham

Mayo Clinic, Rochester, MN, USA

Sue Harrington

Mayo Clinic, Rochester, MN, USA